Preview

Злокачественные опухоли

Расширенный поиск

По следам XXIII Российского онкологического конгресса: дискуссия «Станет ли вся лучевая терапия протонной?»

https://doi.org/10.18027/2224-5057-2019-9-4-5-17

Полный текст:

Аннотация

В статье представлены два мнения в отношении протонной лучевой терапии, ее физических основ, дозиметрических особенностей и клинической эффективности в сравнении с более традиционным фотонным облучением, а также мнение авторов в отношении целесообразности расширения показаний к протонной терапии и открытия новых центров по лечению протонами в мире. Данный обзор стал продолжением дискуссионной сессии по протонной терапии, состоявшейся на XXIII Российском онкологическом конгрессе в ноябре 2019 года.

Об авторах

Н. В. Деньгина
ГУЗ «Областной клинический онкологический диспансер»
Россия

Наталья В. Деньгина, к. м. н., заведующая радиологическим отделением, директор по лечебным вопросам Центра Томотерапии «R-Spei»

Ульяновск



Т. В. Митин
Университет Здоровья и Науки Орегона
Соединённые Штаты Америки

Тимур В. Митин, д. м. н., отделение радиационной медицины

Портленд, США



Н. А. Воробьёв
Медицинский институт им. Березина Сергея
Россия

Николай А. Воробьев, к. м. н., Заведующий отделением конформной лучевой терапии

Санкт-Петербург



Список литературы

1. Климанов В. А. Радиобиологическое и дозиметрическое планирование лучевой и радионуклидной терапии. Часть 2. Лучевая терапия пучками протонов, ионов, нейтронов и пучками с модулированной интенсивностью, стереотаксис, брахитерапия, радионуклидная терапия, оптимизация, гарантия качества. Учебное пособие. М.: НИЯУ МИФИ. — 2011.

2. https://cerncourier.com / a / the-changing-landscape-of-cancer-therapy /

3. Brown AP et al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys. 2013 Jun 1;86 (2):277 – 84. doi: 10.1016 / j. ijrobp. 2013.01.014.

4. Zorlu F, Gurkaynak M, Yildiz F, et al. Conventional external radiotherapy in the management of clivus chordomas with overt residual disease. Neurol Sci. 2000;21:203 – 207.

5. Santoni R, Liebsch N, Finkelstein DM, et al. Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. Int J Radiat Oncol Biol Phys. 1998;41:59 – 68.

6. Ares C, Hug EB, Lomax AJ, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: First long-term report. Int J Radiat Oncol Biol Phys. 2009;75:1111 – 1118.

7. Rombi B, Ares C, Hug EB, et al. Spot-scanning proton radiation therapy for pediatric chordoma and chondrosarcoma: Clinical outcome of 26 patients treated at Paul Scherrer Institute. Int J Radiat Oncol. 2013;86:578 – 584.

8. McDonald MW, Linton OR, Shah MV. Proton therapy for reirradiation of progressive or recurrent chordoma. Int J Radiat Oncol Biol Phys. 2013;87:1107 – 1114.

9. Schild SE, McGinnis WL, Graham D, et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65 (4):1106 – 1111.

10. Bradley JD, Paulus R, Komaki R, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy + / − cetuximab for stage IIIA / IIIB non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617 [abstract]. 53rd Annual Meeting of the American Society for Radiation Oncology, 2011.

11. Cox JD: Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys. 2012;82 (3):1042 – 1044.

12. Sejpal S, Komaki R, Tsao A, et al. Early Findings on Toxicity of Proton Beam Therapy with Concurrent Chemotherapy in Non-small Cell Lung Cancer. Cancer 2011;117:3004 – 3013.

13. Van de Water TA, Lomax AJ, Bijl HP, et al. Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2011;79:1216 – 1224.

14. Steneker M, Lomax A, Schneider U. Intensity modulated photon and proton therapy for the treatment of head and neck tumors. Radiother Oncol. 2006;80:263 – 267.

15. Miralbell R, Crowell C, Suit HD. Potential improvement of three dimension treatment planning and proton therapy in the outcome of maxillary sinus cancer. Int J Radiat Oncol Biol Phys. 1992;22:305 – 310.

16. Miralbell R, Lomax A, Cella L, et al. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys. 2002;54:824 – 829.

17. Van de Water TA, Lomax AJ, Bijl HP, et al. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2012;82: e313‑e319.

18. Yoon M, Ahn SH, Kim J, et al. Radiation-induced cancers from modern radiotherapy techniques: Intensity-modulated radiotherapy proton therapy. Int J Radiat Oncol Biol Phys. 2010;77:1477 – 1485.

19. Weber DC, Chan AW, Lessell S, et al. Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons / protons. Radiother Oncol. 2006;81:243 – 249.

20. Takeda A, Shigematsu N, Suzuki S, et al. Late retinal complications of radiation therapy for nasal and paranasal malignancies: Relationship between irradiated-dose area and severity. Int J Radiat Oncol Biol Phys. 1999;44:599 – 605.

21. Katz TS, Mendenhall WM, Morris CG, et al. Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck. 2002;24:821 – 829.

22. Mock U, Georg D, Bogner J, et al. Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2004;58:147 – 154.

23. Okano S, Tahara M, Zenda S, et al. Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and sinonasal malignancies. Jpn J Clin Oncol. 2012;42:691 – 696.

24. Truong MT, Kamat UR, Liebsch NJ, et al. Proton radiation therapy for primary sphenoid sinus malignancies: Treatment outcome and prognostic factors. Head Neck. 2009;31:1297 – 1308.

25. Van der Laan HP, van de Water TA, van Herpt HE, et al. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study. Acta Oncol. 2013;52:561 – 569.

26. Van de Water TA, Lomax AJ, Bijl HP, et al. Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2011;79:1216 – 1224.

27. Lin R, Slater JD, Yonemoto LT, et al. Nasopharyngeal carcinoma: Repeat treatment with conformal proton therapyddosevolume histogram analysis. Radiology. 1999;213:489 – 494.

28. Armstrong, G. T. Long-term survivors of childhood central nervous system malignancies: the experience of the Childhood Cancer Survivor Study. Eur. J. Paediatr. Neurol. 2010;14:298 – 303.

29. Mertens, A. C. et al. Cause-specific late mortality among 5‑year survivors of childhood cancer: the Childhood Cancer Survivor Study. J. Natl Cancer Inst. 2008;100:1368 – 1379.

30. Morris, E. B. et al. Survival and late mortality in longterm survivors of pediatric CNS tumors. J. Clin. Oncol. 2007;25:1532 – 1538.

31. Chung, C. S. et al. Incidence of second malignancies among patients treated with proton versus photon radiation. Int. J. Radiat. Oncol. Biol. Phys. 2013;87:46 – 52.

32. Zhang, R. et al. A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation. Radiother. Oncol. 2014;113:84 – 88.

33. Mu X, Bjork-Eriksson T, Nill S, et al. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? А comparative treatment planning study. Acta Oncol. 2005;44 (6):554 – 562.

34. Lundkvist, J., Ekman, M., Ericsson, S. R., Jonsson, B. & Glimelius, B. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol. 2005;44:850 – 861.

35. Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016 May 15;122 (10):1483 – 501.

36. https://www.astro.org / uploadedFiles / _MAIN_SITE / Daily_Practice / Reimbursement / Model_Policies / Content_Pieces / ASTROPBTModelPolicy. pdf

37. Glimelius B, Montelius A: Proton beam therapy — Do we need the randomized trials and can we do them? Radiother Oncol 83:105 – 109, 2007

38. Goitein M, Cox JD: Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol 26:175 – 176, 2008

39. Bentzen SM: Randomized controlled trials in health technology assessment: Overkill or overdue? Radiother Oncol 86:142 – 147, 2008.

40. Higgins KA, et al. National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. Int Journal Radiat Oncol Biol Phys 2017;97 (1):128 – 137.

41. Sejpal S, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 2011 117 (13):3004 – 13.

42. Liao Z, et al. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non — Small-Cell Lung Cancer. Journal of Clinical Oncology 2018;36 (18):1813 – 1822.

43. Wang J. et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86 (5):885 – 91.

44. Xi M. et al. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 Nov 1;99 (3):667 – 676.

45. Lin SH et al. Results of a Phase II Randomized Trial of Proton Beam Therapy vs Intensity Modulated Radiation Therapy in Esophageal Cancer. ASTRO 2019.

46. Sheets NC, et al., Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012 Apr 18;307 (15):1611 – 20

47. Dinh, TT et al. Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared To Rectal Balloon Immobilization After Proton Beam Radiotherapy For Localized Prostate Cancer, In Press.

48. Hamstra DA et al., Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiation Oncol Biol Phys 97 (5): 976 – 985, 2017.

49. Wo JH et al. A Pilot Feasibility Study of Definitive Concurrent Chemoradiation with Pencil Beam Scanning Proton Beam in Combination with 5 Fluorouracil and Mitomycin C for Carcinoma of the Anal Canal. Journal of Clinical Oncology 2018;36 (4):733 – 733.

50. Haas-Kogan D. et al. National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. Int J Radiat Oncol Biol Phys. 2018 May 1;101 (1):152 – 168.

51. Feghali et al., Prospective Phase II Randomized Trial Comparing Proton Therapy vs Photon IMRT for newly Diagnosed GBM: Secondary Analysis Comparison of Progression Free survival between RANO vs. Clinical and Radiological Assessment. ASTRO 2019.

52. Corkum MT et al. Online advertising and marketing claims by providers of proton beam therapy: are they guideline based? ASCO 2019 poster.

53. Beyreuther E, et al. Feasibility of proton FLASH effect tested by zebrafish embryo irradiation. Radiother Oncol. 2019 Oct;139:46 – 50.

54. Sheng K. et al. Evolution of Ipsilateral Head and Neck Radiotherapy. Current Cancer Therapy Reviews 2014;10 (4).


Для цитирования:


Деньгина Н.В., Митин Т.В., Воробьёв Н.А. По следам XXIII Российского онкологического конгресса: дискуссия «Станет ли вся лучевая терапия протонной?». Злокачественные опухоли. 2019;9(4):5-17. https://doi.org/10.18027/2224-5057-2019-9-4-5-17

For citation:


Dengina N.V., Mitin T., Vorobjov N.A. Back to the XXIII Russian oncology congress: will radiotherapy soon become entirely the proton one?. Malignant tumours. 2019;9(4):5-17. (In Russ.) https://doi.org/10.18027/2224-5057-2019-9-4-5-17

Просмотров: 200


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)